BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 16568203)

  • 1. [(99m)Tc]Demotate 2 in the detection of sst(2)-positive tumours: a preclinical comparison with [(111)In]DOTA-tate.
    Maina T; Nock BA; Cordopatis P; Bernard BF; Breeman WA; van Gameren A; van den Berg R; Reubi JC; Krenning EP; de Jong M
    Eur J Nucl Med Mol Imaging; 2006 Jul; 33(7):831-40. PubMed ID: 16568203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
    Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
    J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetraamine-modified octreotide and octreotate: labeling with 99mTc and preclinical comparison in AR4-2J cells and AR4-2J tumor-bearing mice.
    Nikolopoulou A; Maina T; Sotiriou P; Cordopatis P; Nock BA
    J Pept Sci; 2006 Feb; 12(2):124-31. PubMed ID: 16059963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [99mTc]Demotate, a new 99mTc-based [Tyr3]octreotate analogue for the detection of somatostatin receptor-positive tumours: synthesis and preclinical results.
    Maina T; Nock B; Nikolopoulou A; Sotiriou P; Loudos G; Maintas D; Cordopatis P; Chiotellis E
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):742-53. PubMed ID: 12029547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 99mTc-Demotate 1: first data in tumour patients-results of a pilot/phase I study.
    Decristoforo C; Maina T; Nock B; Gabriel M; Cordopatis P; Moncayo R
    Eur J Nucl Med Mol Imaging; 2003 Sep; 30(9):1211-9. PubMed ID: 12845487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.
    Wild D; Schmitt JS; Ginj M; Mäcke HR; Bernard BF; Krenning E; De Jong M; Wenger S; Reubi JC
    Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1338-47. PubMed ID: 12937948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 99mTc-N4-[Tyr3]Octreotate Versus 99mTc-EDDA/HYNIC-[Tyr3]Octreotide: an intrapatient comparison of two novel Technetium-99m labeled tracers for somatostatin receptor scintigraphy.
    Gabriel M; Decristoforo C; Maina T; Nock B; vonGuggenberg E; Cordopatis P; Moncayo R
    Cancer Biother Radiopharm; 2004 Feb; 19(1):73-9. PubMed ID: 15068614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide.
    Wester HJ; Schottelius M; Scheidhauer K; Meisetschläger G; Herz M; Rau FC; Reubi JC; Schwaiger M
    Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):117-22. PubMed ID: 12483418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroPET imaging of gene transfer with a somatostatin receptor-based reporter gene and (94m)Tc-Demotate 1.
    Rogers BE; Parry JJ; Andrews R; Cordopatis P; Nock BA; Maina T
    J Nucl Med; 2005 Nov; 46(11):1889-97. PubMed ID: 16269604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation and biological evaluation of [(99m)Tc/EDDA/Tricine/HYNIC(0), BzThi(3)]-octreotide for somatostatin receptor-positive tumor imaging.
    Erfani M; Shafiei M; Mazidi M; Goudarzi M
    Cancer Biother Radiopharm; 2013 Apr; 28(3):240-7. PubMed ID: 23464855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, characterization, conformational analysis of a cyclic conjugated octreotate peptide and biological evaluation of (99m)Tc-HYNIC-His(3)-Octreotate as novel tracer for the imaging of somatostatin receptor-positive tumors.
    Behera A; Banerjee I; De K; Munda RN; Chattopadhayay S; Samanta A; Sarkar B; Ganguly S; Misra M
    Amino Acids; 2013 Mar; 44(3):933-46. PubMed ID: 23090293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.
    de Jong M; Breeman WA; Bernard BF; Bakker WH; Schaar M; van Gameren A; Bugaj JE; Erion J; Schmidt M; Srinivasan A; Krenning EP
    Int J Cancer; 2001 Jun; 92(5):628-33. PubMed ID: 11340564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical evaluation of [99mTc/EDDA/tricine/HYNIC0, 1-Nal3, Thr8]-octreotide as a new analogue in the detection of somatostatin-receptor-positive tumors.
    Gandomkar M; Najafi R; Shafiei M; Mazidi M; Ebrahimi SE
    Nucl Med Biol; 2007 Aug; 34(6):651-7. PubMed ID: 17707805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 99mTc demotate 1: biodistribution and elimination characteristics in rats.
    Kopecky M; Trejtnar F; Laznicek M; Laznickova A; Semecky V; Maina T; Nock B
    Nucl Med Commun; 2005 Jun; 26(6):549-54. PubMed ID: 15891599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy.
    Li WP; Lewis JS; Kim J; Bugaj JE; Johnson MA; Erion JL; Anderson CJ
    Bioconjug Chem; 2002; 13(4):721-8. PubMed ID: 12121126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in biodistribution between 99mTc-depreotide, 111In-DTPA-octreotide, and 177Lu-DOTA-Tyr3-octreotate in a small cell lung cancer animal model.
    Schmitt A; Bernhardt P; Nilsson O; Ahlman H; Kölby L; Forssell-Aronsson E
    Cancer Biother Radiopharm; 2005 Apr; 20(2):231-6. PubMed ID: 15869461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro comparison of renal handling and uptake of two somatostatin receptor-specific peptides labeled with indium-111.
    Trejtnar F; Novy Z; Petrik M; Laznickova A; Melicharova L; Vankova M; Laznicek M
    Ann Nucl Med; 2008 Dec; 22(10):859-67. PubMed ID: 19142704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of 111In-DOTA-NOC and 111I-DOTA-TATE distribution in the target and dose-limiting tissues: conflicting results in vitro and in vivo.
    Cihlo J; Melicharová L; Petrik M; Laznickova A; Laznicek M
    Anticancer Res; 2008; 28(4B):2189-95. PubMed ID: 18751394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.
    Capello A; Krenning E; Bernard B; Reubi JC; Breeman W; de Jong M
    Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1288-95. PubMed ID: 16021448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Up-regulation of somatostatin receptor density on rat CA20948 tumors escaped from low dose [177Lu-DOTA0,Tyr3]octreotate therapy.
    Melis M; Forrer F; Capello A; Bijster M; Bernard BF; Reubi JC; Krenning EP; De Jong M
    Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):324-33. PubMed ID: 17923824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.